Drug intelligence / Profile preview

oxostephanine

Development stage
Preclinical
Modality
Small Molecules
Administration
Not Applicable (no Clinical Use; Tested In Vitro/in Vivo Preclinical Models)
01

Overview

Oxostephanine is a **naturally occurring aporphine alkaloid** isolated from various plants of the genus **Stephania** (notably Stephania dielsiana and Stephania venosa). It is characterized as an inhibitor of **Aurora kinases** (Aurora A, B, and C), which are crucial enzymes involved in cell division. Oxostephanine works by preventing histone H3 phosphorylation at serine 10, inducing mislocalization of Aurora B, and resulting in aneuploidy. It exhibits selective **cytotoxicity against cancer cells**, including ovarian, breast, hepatocellular, leukemia, and other tumor cell lines, while showing minimal toxicity to normal cells. In addition to its anti-mitotic effects, oxostephanine also **inhibits angiogenesis** by attenuating migration and tube formation of endothelial cells. The molecule has not reached clinical application and remains in preclinical research phases, but it is seen as a lead compound for cancer therapy targeting both Aurora kinases and tumor angiogenesis[1][3][4][6].

Other names
oxostephanine
02

Targets

AURKA (Aurora kinase A)AURKB (Aurora kinase B)

Beyond the preview

Go deeper on oxostephanine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxostephanine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call